Scientists at UCL and Great Ormond Street Hospital have developed gene-edited CAR-T cells that can effectively destroy aggressive T-cell acute lymphoblastic leukaemia. These CAR-T cells are universal and, thanks to precise DNA editing, do not damage themselves, which solves a long-standing problem in T-cell-based therapies. In early clinical trials, these cells induced deep and long-lasting remissions even in patients who had already exhausted standard treatment options. The therapy consists in the genetic modification of the patient's T-cells, which subsequently multiply and return to the body, where they target and destroy cancer cells. This approach represents a significant advance in the treatment of one of the most difficult forms of blood cancer. The results suggest that gene-edited CAR-T cells may bring new hope to patients with resistant T-cell leukemia.